What is HiberGene Diagnostics?
HiberGene Diagnostics is an ISO-certified innovator specializing in the design, development, and manufacturing of advanced molecular diagnostics products. Based in Ireland, the company addresses critical inefficiencies in clinical workflows by reducing the time required for diagnostic results. Its product portfolio is engineered for both point-of-care and high-throughput environments, ensuring that healthcare providers can make informed, timely decisions. By integrating multidisciplinary expertise, HiberGene maintains an end-to-end operational model that spans from initial research and development to final market commercialization, effectively challenging traditional, slower diagnostic paradigms.
How much funding has HiberGene Diagnostics raised?
HiberGene Diagnostics has raised a total of $7.7M across 2 funding rounds:
Series A
$2.3M
Series B
$5.5M
Series A (2015): $2.3M with participation from Enterprise Ireland and Kernel Capital
Series B (2017): $5.5M led by Cantor Fitzgerald and Kernel Capital
Key Investors in HiberGene Diagnostics
Cantor Fitzgerald
A global financial services firm providing institutional debt, equity sales, trading, and investment banking services.
Kernel Capital
A venture capital and private equity firm specializing in growth-stage technology and innovation-driven businesses.
Enterprise Ireland
A government agency dedicated to the development and international growth of Irish manufacturing and service-based enterprises.
What's next for HiberGene Diagnostics?
With the recent influx of capital, HiberGene Diagnostics is poised to expand its footprint in the molecular diagnostics market. The strategic focus will likely center on scaling production capacity to meet the rising demand for rapid, near-patient testing solutions. Furthermore, the company is expected to leverage its multidisciplinary team to refine its existing product pipeline and explore new clinical applications. As the healthcare industry shifts toward decentralized testing, HiberGene's ability to maintain high-quality standards while increasing throughput will be a critical driver of its long-term market valuation and competitive advantage.
See full HiberGene Diagnostics company page
